Stakeholder Forum 2011
IMI held its 2011 Stakeholder Forum on Thursday 12 May in Budapest, Hungary as part of the World of Health IT (WoHIT) eHealth week. The event kicked off with a plenary session, jointly organised by IMI and the European Commission’s Information Society, on how knowledge and data management can trigger innovation in healthcare and drug development. Subsequent sessions featured presentations by leading scientists of the first achievements of ongoing IMI projects as well as an overview of IMI’s plans for the future and a glance at IMI’s forthcoming 4th Call for proposals.
The agenda and presentations are below. Video extracts of some of the sessions will be available shortly on IMI’s YouTube Channel [1].
Agenda [2] 
Morning session – Joint Plenary - Knowledge and Data Management for innovation in Drug Development
Introduction to IMI [3]
Prof. Michel Goldman, Executive Director (IMI)
Unlock the value of Health Information for better research and improved health [4]
Mr. Romain Rutten, Vice President, Health Information Sciences (Johnson & Johnson - Janssen Research & Development)
Model-based approaches and decision making in drug development [5]
Dr. Oscar Della Pasqua, Director, Clinical Pharmacology (GlaxoSmithKline)
Knowledge management in IMI: present and future [6]
Ann Martin, Principal Scientific Officer, (IMI)
Afternoon Session 1 - IMI meets the challenges of innovation in the pharmaceutical sector
News from ongoing projects
• PROTECT [7] (Mr. Xavier Kurz, European Medicines Agency)
• eTOX [8] (Prof. Ferran Sanz, Fundació IMIM)
• U-BIOPRED [9] (Prof. Yi-Ke Guo and Dr. Anthony Rowe, Imperial College London)
• PharmaTrain [10] (Prof. Sandor Kerpel-Fronius, Semmelweis University)
Recent projects on knowledge management
• DDMoRE [11] (Dr. Lutz Harnisch, Pfizer)
• Open PHACTS [12] (Dr. Barend Mons, Leiden University)
• EHR4CR [13] (Dr. Andreas Schmidt, Roche)
Afternoon Session 2 - What is coming next at IMI - Part 1
Research and Innovation [14]
Dr. Alain Vanvossel, Adviser, Directorate-General Research & Innovation (European Commission)
The industry priorities [15]
Mr. Richard Bergström, Director General, (EFPIA)
The Vision of the IMI Scientific Committee [16]
Prof. Christian Nöe, Head of Medicinal Chemistry, (University of Vienna), Chair of IMI Scientific Committee
Afternoon Session 3 - What is coming next at IMI – Part 2
The IMI 4th Call for proposals [17]
Ms. Magda Chlebus, RDG Acting Director (EFPIA)
[18]